Atorvastatin
Generic name
Atorvastatin
Brand name
ATC Code
C10AA05
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
Apparent oral clearance of atorvastatin in paediatric subjects appeared similar to adults when scaled allometrically by body weight.(SPC Lipitor)
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Heterozygous familial hypercholesterolaemia |
|---|
|
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Paediatric patients aged from 10 to 17 years of age treated with atorvastatin had an adverse experience profile generally similar to that of patients treated with placebo, the most common adverse experiences observed in both groups, regardless of causality assessment, were infections. No clinically significant effect on growth and sexual maturation was observed. (SPC Lipitor)
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
LIPID MODIFYING AGENTS, PLAIN
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| HMG CoA reductase inhibitors | ||
|---|---|---|
| C10AA03 | ||
| C10AA07 | ||
| C10AA01 | ||
| Bile acid sequestrants | ||
|---|---|---|
| C10AC01 | ||
| Other lipid modifying agents | ||
|---|---|---|
| C10AX09 | ||
Reference
- Pfizer BV, SPC Lipitor (RVG 21081) 13-11-2016, www.cbg-meb.nl
Changes
Therapeutic Drug Monitoring
Overdose
